GAZYVA: an engineered anti-CD20 monoclonal antibody

GAZYVA is a humanized type II anti-CD20 monoclonal antibody that binds to the CD20 antigen, a proven target for CD20+ CLL. It is engineered for reduced fucose content 1-3

Proposed GAZYVA mechanisms of action

ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY (ADCC)
  • GAZYVA binds to and activates immune effector cells in preclinical studies 1,2
GAZYVA MOA ADCC Image
DIRECT CELL DEATH
  • GAZYVA, a type II antibody, directly activates intracellular death signaling pathways as shown in preclinical studies 1-3
GAZYVA MOA Direct Cell Death Image
COMPLEMENT-DEPENDENT CYTOTOXICITY
  • GAZYVA has also been shown to trigger the activation of the complement cascade in preclinical studies 1

GAZYVA was engineered to induce greater ADCC and direct cell death vs rituximab in preclinical studies 1-3

GAZYVA MOA Compared to Rituximab Chart
  • GAZYVA and rituximab bind with similar affinity to overlapping epitopes on CD20

GAZYVA: Engineered for reduced fucose content 1,3

  • Reduced fucose content enhanced binding and activation of immune effector cells in preclinical studies
GAZYVA MOA FC Receptor Binding Image